{"id":16051,"date":"2016-07-05T15:27:35","date_gmt":"2016-07-05T13:27:35","guid":{"rendered":"http:\/\/mabdesign.fr\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/"},"modified":"2016-07-05T15:27:35","modified_gmt":"2016-07-05T13:27:35","slug":"sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/","title":{"rendered":"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"http:\/\/www.sanofi.com\/\" data-cke-saved-href=\"http:\/\/www.sanofi.com\/\">Sanofi<\/a> et <a href=\"http:\/\/www.regeneron.com\/\" target=\"_blank\" data-cke-saved-href=\"http:\/\/www.regeneron.com\/\" rel=\"noopener\">Regeneron Pharmaceuticals, Inc.<\/a> annoncent aujourd\u2019hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale a d\u00e9livr\u00e9 l\u2019autorisation de fabrication et de mise sur le march\u00e9 de Praluent<sup>\u00ae<\/sup> (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie \u00e0 lipoprot\u00e9ines de faible densit\u00e9 (LDL-C) non contr\u00f4l\u00e9e chez certains patients adultes atteints d\u2019hypercholest\u00e9rol\u00e9mie, \u00e0 haut risque cardiovasculaire.<\/p>\n<p><a href=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/Communique_de_presse.pdf\" target=\"_blank\" rel=\"noopener\">Lire le communiqu\u00e9 de presse<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale a d\u00e9livr\u00e9 l\u2019autorisation de fabrication et de mise sur le march\u00e9 de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie \u00e0 lipoprot\u00e9ines de faible densit\u00e9 (LDL-C) non contr\u00f4l\u00e9e chez certains patients adultes atteints d\u2019hypercholest\u00e9rol\u00e9mie, \u00e0 haut risque cardiovasculaire.<\/p>\n","protected":false},"author":1,"featured_media":8343,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,13],"tags":[],"class_list":["post-16051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites","category-nos-adherents"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie - MabDesign<\/title>\n<meta name=\"description\" content=\"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale a d\u00e9livr\u00e9 l\u2019autorisation de fabrication et de mise sur le march\u00e9 de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie \u00e0 lipoprot\u00e9ines de faible densit\u00e9 (LDL-C) non contr\u00f4l\u00e9e chez certains patients adultes atteints d\u2019hypercholest\u00e9rol\u00e9mie, \u00e0 haut risque cardiovasculaire.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale a d\u00e9livr\u00e9 l\u2019autorisation de fabrication et de mise sur le march\u00e9 de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie \u00e0 lipoprot\u00e9ines de faible densit\u00e9 (LDL-C) non contr\u00f4l\u00e9e chez certains patients adultes atteints d\u2019hypercholest\u00e9rol\u00e9mie, \u00e0 haut risque cardiovasculaire.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2016-07-05T13:27:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\" \/>\n\t<meta property=\"og:image:width\" content=\"178\" \/>\n\t<meta property=\"og:image:height\" content=\"77\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie\",\"datePublished\":\"2016-07-05T13:27:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/\"},\"wordCount\":94,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\",\"articleSection\":[\"Actualit\u00e9s\",\"Nos adh\u00e9rents\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/\",\"name\":\"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\",\"datePublished\":\"2016-07-05T13:27:35+00:00\",\"description\":\"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale a d\u00e9livr\u00e9 l\u2019autorisation de fabrication et de mise sur le march\u00e9 de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie \u00e0 lipoprot\u00e9ines de faible densit\u00e9 (LDL-C) non contr\u00f4l\u00e9e chez certains patients adultes atteints d\u2019hypercholest\u00e9rol\u00e9mie, \u00e0 haut risque cardiovasculaire.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png\",\"width\":178,\"height\":77,\"caption\":\"SANOFI\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie - MabDesign","description":"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale a d\u00e9livr\u00e9 l\u2019autorisation de fabrication et de mise sur le march\u00e9 de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie \u00e0 lipoprot\u00e9ines de faible densit\u00e9 (LDL-C) non contr\u00f4l\u00e9e chez certains patients adultes atteints d\u2019hypercholest\u00e9rol\u00e9mie, \u00e0 haut risque cardiovasculaire.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/","og_locale":"en_US","og_type":"article","og_title":"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie - MabDesign","og_description":"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale a d\u00e9livr\u00e9 l\u2019autorisation de fabrication et de mise sur le march\u00e9 de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie \u00e0 lipoprot\u00e9ines de faible densit\u00e9 (LDL-C) non contr\u00f4l\u00e9e chez certains patients adultes atteints d\u2019hypercholest\u00e9rol\u00e9mie, \u00e0 haut risque cardiovasculaire.","og_url":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/","og_site_name":"MabDesign","article_published_time":"2016-07-05T13:27:35+00:00","og_image":[{"width":178,"height":77,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","type":"image\/png"}],"author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie","datePublished":"2016-07-05T13:27:35+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/"},"wordCount":94,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","articleSection":["Actualit\u00e9s","Nos adh\u00e9rents"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/","url":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/","name":"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","datePublished":"2016-07-05T13:27:35+00:00","description":"Sanofi et Regeneron Pharmaceuticals, Inc. annoncent aujourd\u2019hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale a d\u00e9livr\u00e9 l\u2019autorisation de fabrication et de mise sur le march\u00e9 de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie \u00e0 lipoprot\u00e9ines de faible densit\u00e9 (LDL-C) non contr\u00f4l\u00e9e chez certains patients adultes atteints d\u2019hypercholest\u00e9rol\u00e9mie, \u00e0 haut risque cardiovasculaire.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/10\/sanofi.png","width":178,"height":77,"caption":"SANOFI"},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/sanofi-et-regeneron-annoncent-lapprobation-au-japon-de-praluent-alirocumab-dans-le-traitement-de-lhypercholesterolemie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"\u200bSanofi et Regeneron annoncent l\u2019approbation au Japon de Praluent\u00ae (alirocumab) dans le traitement de l\u2019hypercholest\u00e9rol\u00e9mie"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=16051"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16051\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/8343"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=16051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=16051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=16051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}